Pro-Dex Inc New (PDEX) is a publicly traded Healthcare sector company. As of May 21, 2026, PDEX trades at $63.59 with a market cap of $188.88M and a P/E ratio of 18.23. PDEX moved +2.55% today. Year to date, PDEX is +63.92%; over the trailing twelve months it is +42.41%. Its 52-week range spans $23.47 to $70.26. Rallies surfaces PDEX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in PDEX news today?
Pro-Dex Q3 Sales Jump 15% to $19.9M as Net Income Hits $1.20 per Share: Pro-Dex’s Q3 net sales rose 15% to $19.9M, driving gross profit up 6% to $6.1M despite a 2-point margin decline and a 41% increase in operating expenses from the APM acquisition. Net income climbed to $3.9M ($1.20/share), boosted by a $2.3M contingent-value gain.
CABILLOT RAYMOND E sold 7.26K (~$363.22K) on Apr 1, 2025.
CABILLOT RAYMOND E sold 836 (~$41.80K) on Mar 31, 2025.
CABILLOT RAYMOND E sold 842 (~$42.10K) on Mar 28, 2025.
PDEX Analyst Consensus
PDEX analyst coverage data. Average price target: $0.00.
Common questions about PDEX
What changed in PDEX news today?
Pro-Dex Q3 Sales Jump 15% to $19.9M as Net Income Hits $1.20 per Share: Pro-Dex’s Q3 net sales rose 15% to $19.9M, driving gross profit up 6% to $6.1M despite a 2-point margin decline and a 41% increase in operating expenses from the APM acquisition. Net income climbed to $3.9M ($1.20/share), boosted by a $2.3M contingent-value gain.
Does Rallies summarize PDEX news?
Yes. Rallies summarizes PDEX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is PDEX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PDEX. It does not provide personalized investment advice.
